Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Assets data on record, last reported at $497.6 million in Q1 2026.

  • On a quarterly basis, Assets rose 64.74% to $497.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $497.6 million, a 64.74% increase, with the full-year FY2025 number at $512.4 million, up 62.71% from a year prior.
  • Assets reached $497.6 million in Q1 2026 per RAPP's latest filing, down from $512.4 million in the prior quarter.
  • Over the last five years, Assets for RAPP hit a ceiling of $535.3 million in Q3 2025 and a floor of $155.4 million in Q4 2023.
  • A 4-year average of $364.5 million and a median of $331.1 million in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: surged 102.63% in 2024, then dropped 17.51% in 2025.
  • Tracing RAPP's Assets over 4 years: stood at $155.4 million in 2023, then surged by 102.63% to $314.9 million in 2024, then skyrocketed by 62.71% to $512.4 million in 2025, then fell by 2.89% to $497.6 million in 2026.
  • Business Quant data shows Assets for RAPP at $497.6 million in Q1 2026, $512.4 million in Q4 2025, and $535.3 million in Q3 2025.